Organon To Report Third Quarter Results and Host Conference Call on November 3, 2022

Rhea-AI Summary

Organon (NYSE: OGN) will announce its third quarter 2022 financial results on November 3, 2022, before a conference call at 8:30 a.m. EDT. The event can be accessed via a webcast on the company’s website, with a replay available shortly after. Organon focuses on improving women’s health and has a diverse portfolio of over 60 products, supported by strong cash flows. With a significant global presence, the company aims to expand its biosimilars business and collaborate with biopharmaceutical innovators.

Positive

• Strong cash flows support investments in innovation.
• Diverse product portfolio of over 60 medicines.
• Expanding biosimilars business.

Negative

• None.

JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global women’s healthcare company will release its third quarter 2022 financial results on November 3, 2022, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.

Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/. A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website.

Institutional investors and analysts interested in participating in the call must register in advance using conference ID# 58511-502 and by clicking on this link: https://conferencingportals.com/event/ZGyfDfjk.

Following registration, participants will receive a confirmation email containing details on how to join the conference call, including dial-in information and a unique passcode and registrant ID. Pre-registration will allow participants to bypass an operator and be placed directly into the call.

About Organon

Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,300 employees with headquarters located in Jersey City, New Jersey.

For more information, visit http://www.organon.com and connect with us on LinkedIn and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221020005048/en/

Organon Media Contacts:

Karissa Peer

(614) 314-8094

Kate Vossen

(732) 675-8448

Organon Investor Contacts:

Jennifer Halchak

(201) 275-2711

Source: Organon & Co.

FAQ

When will Organon release its Q3 2022 financial results?

Organon will release its Q3 2022 financial results on November 3, 2022.

What time is Organon's Q3 2022 conference call?

The conference call for Organon's Q3 2022 results is scheduled for 8:30 a.m. EDT.

How can I access Organon's Q3 2022 webcast?

You can access Organon's Q3 2022 webcast through their investor relations website.

What is the focus of Organon as a healthcare company?

Organon focuses on improving women's health with a portfolio of over 60 products.

What are Organon's business development plans?

Organon plans to expand its biosimilars business and collaborate with biopharmaceutical innovators.